FREE SHIPPING ON ORDERS OVER $200 Now testing for heavy metals and endotoxins ≥98.5% purity Third-party HPLC tested COA on every batch Fast, discreet US shipping
MOTS-c 10mg research peptide vial
Growth & Longevity

MOTS-c

Mitochondrial ORF peptide

A mitochondrial-derived peptide studied in metabolic and longevity research.

From $90

In stock · ships in 1–2 business days

  • ✓ 99.51% purity (tested)
  • ✓ HPLC + mass-spec tested
  • ✓ View batch COA
  • ✓ Discreet US shipping
mitochondriallongevity research

Research Summary

MOTS-c is a mitochondrial-derived peptide studied in preclinical research for its role in metabolic homeostasis, AMPK signaling, and cellular stress-response models. For laboratory research use only.

Handling

Store the sealed lyophilized peptide at -20°C, protected from light and moisture. Let the vial reach room temperature before opening to limit condensation. Any further handling should follow your laboratory's own validated procedures, using appropriate protective equipment.

Research overview

MOTS-c: what the research shows

Reviewed October 12, 2026 against PubMed and primary sources. For research context only, not medical advice.

What is MOTS-c?

MOTS-c is a 16-amino-acid peptide encoded not in the cell nucleus but in mitochondrial DNA. Its name stands for mitochondrial open reading frame of the 12S rRNA type-c. It was described in 2015 by a group at the University of Southern California, who found a short open reading frame inside the mitochondrial 12S ribosomal RNA gene that codes for the peptide [2]. PubChem records its sequence as MRWQEMGYIFYPRKLR [1].

MOTS-c belongs to a small family of so-called mitochondrial-derived peptides, alongside humanin. Its discovery drew attention because it suggested that the mitochondrial genome may also encode signaling peptides that act beyond the mitochondrion [2] [3].

A 2023 review summarized the field this way: MOTS-c is expressed in several tissues and found in plasma, plasma levels were reported to fall with age, and the peptide has been studied in models of glucose metabolism, cardiovascular disease, and inflammation. The same review noted that no effective clinical application of MOTS-c had been developed [9].

MOTS-c molecular identity
SequenceMet-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg (MRWQEMGYIFYPRKLR)
Length16 amino acids
Molecular formulaC101H152N28O22S2
Molecular weight2174.6 g/mol
CAS number1627580-64-6
PubChem CID146675088
Full nameMitochondrial open reading frame of the 12S rRNA type-c

Mechanisms studied

Most of the mechanistic work comes from the discovering laboratory and its collaborators, and several of those authors have disclosed commercial interests in MOTS-c-related development in the papers themselves [3] [5]. Since 2022, independent groups in Spain, Denmark, South Korea, and China have published mechanistic work of their own, summarized below, but most individual pathways have still been described by only one or two laboratories.

Folate metabolism and AMPK activation

In the original 2015 study, the authors reported that skeletal muscle appeared to be the primary target tissue. At the cellular level, MOTS-c inhibited the folate pathway and the de novo purine synthesis linked to it, leading to activation of AMP-activated protein kinase (AMPK) [2].

Translocation to the nucleus

A 2018 study from the same group reported that under metabolic stress, such as glucose restriction, MOTS-c moved from the cytoplasm into the nucleus in an AMPK-dependent manner. There it influenced a broad set of nuclear genes, including genes with antioxidant response elements, and interacted with stress-responsive transcription factors such as NRF2 [3]. The authors framed this as a mitochondrial-encoded factor regulating the nuclear genome, a direction of control that had not previously been described.

CK2 as a direct binding partner

A 2024 study reported that MOTS-c bound directly to protein kinase CK2 and activated it in cell-free systems. In mice, effects on muscle atrophy and muscle glucose uptake were blunted when CK2 activity was suppressed. The authors also reported tissue-specific behavior: the peptide bound CK2 in both fat and muscle but increased CK2 activity in muscle while reducing it in fat [5].

Myostatin and atrophy signaling

Earlier work from the group connected these findings. In palmitic-acid-stressed C2C12 myotubes, MOTS-c prevented atrophy, and in diet-induced obese mice it lowered plasma myostatin. The proposed chain ran from CK2 activation to PTEN inhibition, increased mTORC2 activity, AKT phosphorylation, and inhibition of the FOXO1 transcription factor that drives myostatin and other atrophy genes [6].

STAT3 and a putative SH2-binding motif

An independent group in Valencia identified, by sequence analysis, a putative Src homology 2 (SH2) binding motif in the YIFY region of MOTS-c and made a mutant peptide with a single tyrosine-to-phenylalanine change (Y8F). In human LHCN-M2 and mouse C2C12 muscle progenitor cells, the native peptide increased myotube formation, protected nuclear myogenin staining against interleukin-6, and blocked IL-6-induced STAT3 transcriptional activity, while the Y8F mutant did none of these [15]. A single-residue control of this kind is a useful design for laboratories testing sequence specificity.

Mitochondrial bioenergetics through PGC-1α and AMPK

A 2026 study from the University of Copenhagen used two transgenic mouse strains to ask whether MOTS-c changes muscle mitochondrial function itself. The authors reported improved mitochondrial bioenergetic performance that depended on both the transcriptional coactivator PGC-1α and AMPK, without an apparent change in respiratory protein content, along with lower mitochondrial reactive oxygen species emission and less oxidative protein damage [16].

Nuclear transport in endothelial cells

In rat lung ischemia-reperfusion models, a 2025 study found the strongest MOTS-c up-regulation in endothelial cells. Under hypoxia-reoxygenation, reactive oxygen species triggered CK2-dependent phosphorylation of the motor protein MYH9, which allowed MOTS-c to bind MYH9 and actin complexes and move into the nucleus. Sequencing experiments showed MOTS-c at the promoters of antioxidant genes such as HMOX1 and NQO1 [17]. This adds a candidate transport route to the nuclear-translocation model first described in 2018 [3].

Areas of research

Metabolic models

In the 2015 discovery paper, the authors reported that MOTS-c prevented age-dependent insulin resistance in mice, as well as the insulin resistance and obesity induced in mice by a high-fat diet [2]. A 2021 study tested a naturally occurring variant, K14Q MOTS-c, produced by an East Asian mitochondrial DNA polymorphism (m.1382A>C). In high-fat-fed male mice, the standard peptide was associated with lower weight and better glucose tolerance, while the K14Q variant was not, and in cell experiments the variant showed reduced insulin-sensitizing activity [7].

Skeletal muscle models

Skeletal muscle is the most consistent thread in MOTS-c research. Beyond the atrophy and CK2 work above [5] [6], a 2021 study reported that MOTS-c regulated nuclear genes related to metabolism and proteostasis, altered skeletal muscle metabolism, and influenced myoblast adaptation to metabolic stress. In that study, mice of several ages that received MOTS-c showed higher scores on physical-capacity tests than controls [4].

Pancreatic islet models

A 2025 study reported that MOTS-c levels fell with age and senescence in mouse pancreatic islet cells. Exposing aged mouse islets to MOTS-c reduced senescence markers by altering nuclear gene expression and metabolites, and the authors reported reduced islet senescence and improved glucose tolerance in two mouse models of diabetes [18].

Bone models

A 2023 review of bone research summarized reports that MOTS-c promoted osteoblast proliferation, differentiation, and mineralization and inhibited osteoclast formation in experimental models, while noting that the mechanism linking exercise, MOTS-c, and bone remains unclear [19].

Other models

Reviews also describe MOTS-c research in cardiovascular and inflammatory models [9]. A 2026 narrative review of approved and unapproved peptides included MOTS-c and concluded that, although many of the unapproved peptides it covered showed favorable outcomes in animal models, rigorous human safety data were scarce [10].

Open research questions

  • Whether the AMPK, nuclear-translocation, and CK2 models are separate mechanisms or parts of one pathway.
  • How much of the published effect reproduces outside the discovering laboratory, now that independent groups have begun reporting related but not identical mechanisms [15] [16] [17].
  • How the endogenous peptide is regulated, given that circulating levels were reported to change with age and exercise [4] [9].

State of the human evidence

Human research on MOTS-c so far is observational: it measures the body's own MOTS-c or studies a genetic variant. It does not test the synthetic peptide.

  • Exercise. The 2021 Nature Communications study reported that exercise increased endogenous MOTS-c in human skeletal muscle and in circulation [4]. A separate randomized exercise study in 30 volunteers found that circulating humanin rose after endurance exercise, while MOTS-c showed only a trend toward an increase [8].
  • Genetics. In a meta-analysis of three cohorts totaling 27,527 people, men carrying the m.1382A>C allele, which produces K14Q MOTS-c, had a higher prevalence of type 2 diabetes, while women did not [7]. This is an association study, not evidence about the synthetic peptide.
  • Correlations. Plasma MOTS-c levels were inversely correlated with myostatin levels in human subjects [6], and circulating MOTS-c was lower in people with type 2 diabetes than in healthy controls [18]. In patients undergoing cardiopulmonary bypass surgery, the early rise in serum MOTS-c was studied as a biomarker of later lung injury [17].
  • Source of circulating MOTS-c. In a one-legged knee-extensor exercise model, interstitial MOTS-c rose but the arterio-venous difference across the working leg did not change, which led the Copenhagen authors to suggest that skeletal muscle may not be the source of circulating MOTS-c during exercise [16].

We found no published randomized, controlled clinical trial of synthetic MOTS-c in PubMed as of the review date. FDA's 2026 compounding safety-risk page states that the agency had no human exposure data for MOTS-c [11]. Findings in mice and cultured cells should not be read as evidence of safety or benefit in people.

Regulatory status

  • Not FDA approved. MOTS-c is not an FDA-approved drug. FDA's list of bulk drug substances that may present significant safety risks (content current as of April 22, 2026) shows MOTS-c among substances whose nominations were withdrawn, noting that compounded drugs containing it may pose a significant risk of immunogenicity for certain routes, complexities in peptide impurities and characterization, and no available human exposure data [11].
  • Advisory committee vote. At its July 23-24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted in favor of recommending MOTS-c for the 503A bulks list [12]. The committee's votes are recommendations and are not binding on FDA, and pharmacies may not compound a substance on that basis until final rulemaking is in place [13]. FDA had not completed any such action at the time of this review.
  • Sport. The World Anti-Doping Agency names MOTS-c under S4.4.1, metabolic modulators (activators of AMPK), prohibited at all times [14].

Rejuvatide supplies MOTS-c strictly as a research chemical for in vitro and laboratory use. It is not sold for human or veterinary use.

Testing and quality

Every Rejuvatide lot of MOTS-c is tested by an independent laboratory for purity by HPLC and identity by LC-MS, and the lot also carries an endotoxin certificate. The current certificates are shown below and in our COA library, where you can match the lot number on your vial to its report. Certificates are published exactly as the laboratory issued them.

For another mitochondria-focused research compound, see SS-31, or the coenzyme NAD+. Browse all related research compounds, or see our FAQ for ordering questions.

Storage of lyophilized material

MOTS-c ships as a lyophilized (freeze-dried) powder. For long-term storage, keep sealed vials at -20°C, protected from light and moisture. Allow a vial to reach room temperature before opening to limit condensation. Handling of any prepared solutions should follow your laboratory's own validated procedures.

Certificate of Analysis

Independently tested by Freedom Diagnostics. This is the certificate for the current batch of MOTS-c.

99.51%HPLC purity
Lot 60730-34Tested batch

Your browser cannot display the PDF inline. Open the Certificate of Analysis.

MOTS-c FAQ

What is MOTS-c?

MOTS-c is a 16-amino-acid peptide (MRWQEMGYIFYPRKLR) encoded in the mitochondrial 12S rRNA gene. It is studied in preclinical research on AMPK signaling, skeletal muscle metabolism, and cellular stress responses.

Why is MOTS-c called a mitochondrial-derived peptide?

Because it is encoded by a short open reading frame in mitochondrial DNA rather than in the nuclear genome. Humanin is another member of this small peptide family.

Is MOTS-c FDA approved?

No. An FDA advisory committee voted in July 2026 to recommend MOTS-c for the 503A compounding bulks list, but that vote is non-binding and does not make MOTS-c an approved drug.

Is MOTS-c banned in sport?

Yes. WADA names MOTS-c under S4.4.1 of its Prohibited List as an AMPK activator, prohibited at all times.

Has MOTS-c been tested in human clinical trials?

Published human research so far measures natural MOTS-c levels or studies a genetic variant. We found no published randomized controlled trial of the synthetic peptide as of October 2026.

How is Rejuvatide MOTS-c tested?

Each lot is tested by an independent laboratory for HPLC purity and LC-MS identity, with a separate endotoxin certificate, all published in the COA library and matched to the lot number on the vial.

Is MOTS-c for human use?

No. Rejuvatide sells MOTS-c for laboratory research use only. It is not for human or veterinary use, and nothing on this site is medical advice.

References

  1. PubChem. Mots-c, Compound CID 146675088. National Library of Medicine. Source
  2. Lee C, Zeng J, Drew BG, et al. Cell Metab. 2015;21(3):443-54. PubMed 25738459
  3. Kim KH, Son JM, Benayoun BA, et al. Cell Metab. 2018;28(3):516-524.e7. PubMed 29983246
  4. Reynolds JC, Lai RW, Woodhead JST, et al. Nat Commun. 2021;12(1):470. PubMed 33473109
  5. Kumagai H, Kim SJ, Miller B, et al. iScience. 2024;27(11):111212. PubMed 39559755
  6. Kumagai H, Coelho AR, Wan J, et al. Am J Physiol Endocrinol Metab. 2021;320(4):E680-E690. PubMed 33554779
  7. Zempo H, Kim SJ, Fuku N, et al. Aging (Albany NY). 2021;13(2):1692-1717. PubMed 33468709
  8. von Walden F, Fernandez-Gonzalo R, Norrbom J, et al. J Appl Physiol (1985). 2021;131(3):1035-1042. PubMed 34351816
  9. Zheng Y, Wei Z, Wang T. Front Endocrinol (Lausanne). 2023;14:1120533. PubMed 36761202
  10. Mendias CL, Awan TM. Sports Med. 2026;56(8):1921-1935. PubMed 41966639
  11. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). Source
  12. Regulatory Affairs Professionals Society. FDA advisory committee backs two more peptides, rejects one for compounding list (July 24, 2026). Source
  13. National Community Pharmacists Association. FDA advisory committee nominates six peptides for pharmacies to compound (July 31, 2026). Source
  14. World Anti-Doping Agency. The 2026 Prohibited List, S4.4 Metabolic Modulators. Source
  15. García-Benlloch S, Revert-Ros F, Blesa JR, et al. Peptides. 2022;155:170840. PubMed 35842023
  16. Gudiksen A, Hansen CC, van der Stede T, et al. Free Radic Biol Med. 2026;246:682-696. PubMed 41520850
  17. Li X, Zhan F, Qiu G, et al. Redox Biol. 2025;84:103681. PubMed 40403491
  18. Kong BS, Lee H, L'Yi S, et al. Exp Mol Med. 2025;57(8):1861-1877. PubMed 40855115
  19. Yi X, Hu G, Yang Y, et al. Front Physiol. 2023;14:1149120. PubMed 37200834